Asahi Kasei To Acquire Calliditas Therapeutics For SEK 11.8 Billion

Asahi Kasei Corp. declares that Asahi Kasei will acquire the shares of the drug organization Calliditas to make Calliditas an entirely owned subsidiary of Asahi Kasei through a deliberate delicate proposal for Calliditas. The Tender Offer will incorporate a simultaneous proposal by Asahi Kasei to acquire all American Depositary Shares (ADS), each addressing two shares in Calliditas, which will be directed compliant with the protections rules of the US.

The japan based chemical firm will propose to secure the conventional shares of Calliditas, which are all recorded on Nasdaq Stockholm, and American Depositary Portions of Calliditas, which are recorded on Nasdaq Global Select Market and each address two ordinary shares, offering SEK 208 for every offer (roughly JPY 3,076) to the investors of Calliditas and SEK 416 to the holders of American Depositary Shares of Calliditas, through the Tender Offer to make Calliditas an entirely claimed subsidiary of Asahi Kasei. 

The Tender Offer has been endorsed by the Board of Directors of Asahi Kasei and the Board of Directors of pharmaceutical firm suggests the investors and holders of American Depositary Shares of Calliditas to acknowledge the Delicate Proposition. Asahi Kasei intends to acquire Calliditas for the complete value worth of around SEK 11.8 billion (roughly JPY 174 billion).